A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 21 Nov 2017
At a glance
- Drugs Cabozantinib (Primary)
- Indications Liver cancer
- Focus Registrational; Therapeutic Use
- Acronyms CELESTIAL
- Sponsors Exelixis
- 21 Nov 2017 Results presented in an Exelixis media release.
- 21 Nov 2017 According to an Exelixis media release, data will be presented as a late-breaking oral presentation at the 2018 American Society of Clinical Oncologys Gastrointestinal Cancers Symposium (ASCO-GI).
- 17 Oct 2017 Planned End Date changed from 1 Oct 2016 to 1 Oct 2018.